Skip to main content

Table 1 Descriptive statistics

From: Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine

PANEL A

Variable

Category 

Mean

SD

n

Age

44.05

11.46

359

Earnings (EUR)a

46,739

27,185

335

MMD

CMb

12.95

7.09

199

HFEMc

10.45

3.49

80

LFEMd

5.20

1.08

83

MHD

CM

18.38

7.76

197

HFEM

12.76

5.47

80

LFEM

7.96

4.35

83

PANEL B

Variable

Category

Number (%)

N e

Gender

Female

350 (97.5%)

359

Male

9 (2.5%)

359

Education

Elementary school

13 (3.6%)

362

 

Qualifying education

2 (0.6%)

362

 

Gymnasium

23 (6.4%)

362

 

Vocational training

55 (15.2%)

362

 

Short higher education

23 (6.4%)

362

 

Bachelor’s degree

60 (16.6%)

362

 

Medium higher education

91 (25.1%)

362

 

Long higher education

92 (25.4%)

362

 

Other

3 (0.8%)

362

Employment

Full-time

126 (34.9%)

361

 

Self-employed

23 (6.4%)

361

 

Part-time

96 (26.6%)

361

 

Student

29 (8.0%)

361

 

Unemployed

11 (3.0%)

361

 

Not active in the labour market

52 (14.4%)

361

 

Other

24 (6.6%)

361

Civil status

Married

188 (52.1%)

361

 

In a relationship

97 (26.9%)

361

 

Single

73 (20.2%)

361

 

Does not want to answer/other

3 (0.8%)

361

Migraine type

CM

199 (55.0%)

362

 

HFEM

80 (22.1%)

362

 

LFEM

83 (22.9%)

362

Share receiving treatment with CGRP-mAbs

16.3%

362

Share receiving other preventive treatment, disregarding the CGRP-mAb-treatment group

33.3%

303

  1. SD standard deviation; MHD monthly headache days; MMD monthly migraine days; CGRP calcitonin gene-related peptide; mAbs monoclonal antibodies.
  2. a Patients with missing information on earnings are assigned the average earnings from Statistics Denmark based on their gender and educational attainment. This implies that all 362 respondents have average earnings of €46,919 (SD = 26,879).
  3. b CM is defined according to ICHD-3 [14].
  4. c HFEM is defined as patients reporting at least eight MMD but fewer than 15 MHD [15].
  5. d LFEM is defined as patients with four to seven MMD [15].
  6. e The number of respondents in the total sample for which the shares are calculated differs marginally as some respondents did not answer all questions, e.g., on gender and employment.